Lactobacillus paracasei strain and use thereof

IN595483BActive Publication Date: 2026-07-15KO BIOLABS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
IN202017049053
Authority / Receiving Office
IN · IN
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-05-09
Filing Date
2020-11-10
Publication Date
2026-07-15
Estimated Expiration
2039-05-09

AI Technical Summary

Technical Problem

Current treatments for intestinal diseases, allergic diseases, autoimmune diseases, and inflammatory diseases are inadequate, with existing probiotics not effectively addressing symptoms such as irritable bowel syndrome, inflammatory bowel disease, atopic dermatitis, and allergic reactions, and existing treatments often come with side effects or limited efficacy.

Method used

The use of Lactobacillus paracasei KBL382, KBL384, and KBL385 strains, either as a culture, lysate, or extract, in food or pharmaceutical compositions to improve intestinal health, treat or prevent intestinal diseases, allergic diseases, autoimmune diseases, and inflammatory diseases by enhancing immune regulation and reducing inflammation.

Benefits of technology

These strains demonstrate significant immunomodulatory and anti-inflammatory effects, improving intestinal health, reducing disease symptoms, and alleviating allergic reactions, with potential therapeutic benefits comparable to commercial treatments.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention pertains to: a novel human-derived probiotic strain that is Lactobacillus paracasei KBL382, Lactobacillus paracasei KBL384, or Lactobacillus paracasei KBL385; and a use of the strain for improving intestinal health and treating or preventing intestinal diseases. The strain according to the present invention has excellent anti-inflammatory and immunomodulatory functions, has a superb strengthening effect on tight junctions of the intestinal tract wall, suppresses enteritis-induced weight loss and colon length reduction, thereby exhibiting a therapeutic effect for enteritis, and significantly alleviates the symptoms of atopic dermatitis. Therefore, the strain can be useful as a probiotic material for enhancing anti-inflammatory effects, strengthening immunity, improving intestinal health functions, and alleviating allergic diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Name of the invention: Lactobacillus paracasei strain and its useTechnical field[One]The present invention relates to a Lactobacillus paracasei strain and its use, and in more detail, the Lactobacillus paracasei KBL382 strain, the Lactobacillus paracasei KBL384 strain or the Lactobacillus paracasei KBL385 strain, the cells of the strain, the Allergy symptom improvement, immune regulation ability improvement, inflammation symptom improvement, atopic dermatitis improvement, health function for improving intestinal health containing an effective amount of at least one selected from the group consisting of the culture of the strain, the lysate of the strain and the extract of the strain It relates to a composition for food, and a pharmaceutical composition for the treatment or prevention of allergic diseases, autoimmune diseases, inflammatory diseases, atopic dermatitis and / or intestinal diseases.[2]Background[3]Probiotics refer to microorganisms having antibacterial and enzymatic activities that help balance microorganisms in the intestine and products produced by the microorganisms. In addition, probiotics are defined as live bacteria in the form of single or complex strains that are supplied to humans or animals in the form of dried cells or fermented products, thereby improving the intestinal flora. The characteristics that probiotics must have is that the human gut is the habitat, and it is non-pathogenic, non-toxic, and must survive while going to the gut. Furthermore, it must maintain viability and activity before being consumed in the delivery food, be sensitive to antibiotics used to prevent infection, and not possess plasmids with antibiotic resistance. In addition, it must be resistant to acids, enzymes, and bile in the intestinal environment.[4]These probiotics include Bacillus sp. , which has excellent ability to produce digestive enzymes (amylase, protease, lipase, cellulase, phosphatase ), Lactobacillus sp. , which produces lactic acid, and causes odor remaining in the feces of livestock . Examples include Photosynthetic bacteria , which prevent odor induction by using substances (ammonia, hydrogen sulfide, amines, etc.) for metabolism .[5]In particular, Bacillus species and Lactobacillus species are known as very useful probiotics because there are strains that produce various antibacterial substances. These lactic acid bacteria produce an antimicrobial peptide called bacteriocin, which has an antibacterial mechanism that is not related to the mechanism of antibiotic resistance. Bacteriocin has polymorphic characteristics that differ considerably in molecular weight, biochemical properties, and antibacterial range and mechanisms for the host. Klaenhammer defines it as a protein or protein complex that has direct antibacterial activity against bacteriocin-producing bacteria and nearby species.[6]On the other hand, irritable bowel syndrome (Irritable Bowel Syndrome) is a symptom characterized by discomfort associated with abdominal pain and / or changed bowel behavior or bowel habits, and such symptoms are not described as structural or biochemical abnormalities. A feeling of urgency, bloating, and incomplete bowel movement are also common symptoms of IBS. Thus, this disease is classified into functional gastrointestinal disorders including diseases such as functional bloating, non-cardiac chest pain, non-ulcer indigestion and chronic constipation or diarrhea. In particular, IBS has an enormous effect on morbidity and quality of life beyond abdominal pain and discomfort, since related symptoms act on both the patient's well-being and normal functional aspects.[7]Inflammatory Bowel Disease is a disease in which abnormal chronic inflammation in the intestine repeats improvement and recurrence, and includes all inflammatory diseases of the intestine.Specific examples include Crohn's disease, ulcerative colitis, or Behcet's disease. ), but is not limited thereto. A great deal of research is being conducted in the field of drug development for the treatment of IBS and IBD. In this regard, various antidepressants are popularly used, although their efficacy is moderate in clinical trials and their clinical utility is limited due to considerable side effects. Serotonin preparations are also proven to be effective against overall IBS symptoms. However, due to problems with safety in recent years, its application has been limited in various ways, and thus, interest in developing new therapeutic agents for IBS is greatly amplified.[8]On the other hand, allergy is a biochemical phenomenon that shows a specific and modified reaction to a foreign substance (antigen), and when a foreign substance causes symptoms, it is called an allergen, and the resulting disease is called an allergic disease. do. Allergy is a pathological process in a living body that appears as a result of an antigen-antibody reaction, which is the cause of its occurrence, and is generally classified into four types from the time required to induce a reaction and the type of complement involvement. Among them, type 1 is anaphylatctic (cytotropic; immediate type), and target organs are mainly digestive organs, skin, and lungs.General symptoms include gastrointestinal allergy, dammargin, atrophic dermatitis, allergic rhinitis and bronchial asthma. There is this. The pathological mechanism of type 1 activates target cells by contacting the antigen with IgE antibodies attached to the surface of mast cells and basophils, secreting chemical media such as histamine, leukotriene, and PAF to contract blood vessels and smooth muscles. It is known that it is said to be made, but it is often combined with the fourth type (delayed type). That is, the anaphylaxis and allergic reactions are caused by various changes that occur in mast cells. The activation of mast cells that induce degranulation is the binding of antigens, anti-IgE, and lectins to Fc receptors. It is caused by drugs such as stimulation of anaphylatoxin, calcium ionopore, compound 48 / 80, and synthetic cortical stimulating hormones such as codeine.[9]Mast cells and basophils in the blood are known as major cells in the body that cause various allergic diseases such as allergic rhinitis, allergic dermatitis, asthma, food allergy and anaphylactic shock. These cells are antibodies that cause allergies on the cell surface. It has a receptor for phosphorus IgE (FcRI), which is stimulated by substances that cause allergies (antigens, allergens) to secrete various allergens that it has to the outside of cells (Kim K et al, Eur J Pharmacol, 581:191-203, 2008).

[10] Among allergic diseases, atopic dermatitis, as is well known, is a chronic recurrent skin disease that affects newborns or children and may persist until adulthood. Atopic dermatitis is an inflammatory skin disease associated with local invasion of IL-4 and IL-5-producing T lymphocytes, such as asthma and allergic rhinitis. It causes overproduction of immunoglobulins (Ig) and eosinophilia, and increases serum IgE levels. 80-90% of subjects with positive skin tests for food and inhalable allergens were demonstrated to have atopic dermatitis.

[11] Various treatments have emerged to treat or prevent allergic diseases including atopic dermatitis, but no effective treatment methods exist yet. Although some drug-based treatments are known, they are resistant to short-term use of drugs for treatment, and can cause considerable side effects when taking long-term drugs, so the treatment of allergic diseases by drugs is recently avoided. There are many cases in which irritation symptoms such as allergies and other skin itchiness or skin redness cannot be improved without treatment.

[12] WO 96 / 29083 and EP 554418 are described in Lactobacillus plantarum 299v (DSM 6595) and Lactobacillus casei ssp. Rhamnosus ( Lactobacillus casei ssp.rhamnosus ) 271 (DSM 6594), etc., two types of Lactobacillus strains forming colonies in the intestine were disclosed. EP 415941 discloses a method of preparing a nutritional composition comprising enzymatic treatment of oat gruel prior to mixing with lactobacilli. US Patent 7195906 discloses a strain of Bifidobacterium isolated from the human gastrointestinal tract that has been excised and washed to treat inflammatory diseases, particularly gastrointestinal inflammatory effects such as IBD and IBS.

[13] However, strains showing excellent effects on improving intestinal health including inflammatory bowel disease and irritable bowel syndrome and strains showing excellent effects on improving allergy symptoms have not yet been found, and studies to find strains showing the above effects have been conducted by numerous research institutes. The situation continues.

[14] Therefore, the present inventors focus on the fact that the health promotion effect of probiotics is strain-specific rather than general characteristics of genus and species, and the (Report of a joint FAO / WHO working group on drafting guidelines for the evaluation of probiotics in food, London Ontario, Canada, 2002), a variety of strains were screened to identify novel strains with excellent immunomodulatory effect, anti-inflammatory activity, allergy improvement, gut health improvement, and gut disease treatment effect. The present invention was completed by confirming the excellent therapeutic effect.

[15]

[16] Summary of the invention

[17] The object of the present invention is to improve intestinal health, treat or prevent intestinal diseases, enhance immune regulation ability, treat or prevent autoimmune diseases, improve allergy symptoms, improve inflammatory symptoms, improve and treat atopic dermatitis. To provide.

[18] In order to achieve the above object, the present invention provides a Lactobacillus paracasei KBL382 (accession number KCTC13509BP) strain, a Lactobacillus paracasei KBL384 (accession number KCTC13510BP) strain or a Lactobacillus paracasei KBL385 (accession number KCTC13511BP) strain. do.

[19] The present invention also provides a Lactobacillus paracasei KBL382 (accession number KCTC13509BP) strain, a Lactobacillus paracasei KBL384 (accession number KCTC13510BP) strain or Lactobacillus paracasei KBL385 (accession number KCTC13511BP) strain, a culture of the strain, It provides a composition for food or food addition containing an effective amount of at least one selected from the group consisting of the lysate of the strain and the extract of the strain.

[20] The present invention also provides a Lactobacillus paracasei KBL382 (accession number KCTC13509BP) strain, a Lactobacillus paracasei KBL384 (accession number KCTC13510BP) strain or Lactobacillus paracasei KBL385 (accession number KCTC13511BP) strain, a culture of the strain, It provides a pharmaceutical composition for the treatment or prevention of intestinal diseases containing an effective amount of at least one selected from the group consisting of the lysate of the strain and the extract of the strain.

[21] The present invention also provides a Lactobacillus paracasei KBL382 (accession number KCTC13509BP) strain, a Lactobacillus paracasei KBL384 (accession number KCTC13510BP) strain or Lactobacillus paracasei KBL385 (accession number KCTC13511BP) strain, a culture of the strain, It provides a pharmaceutical composition for the treatment or prevention of allergic diseases containing an effective amount of at least one selected from the group consisting of the lysate of the strain and the extract of the strain.

[22] The present invention also provides a Lactobacillus paracasei KBL382 (accession number KCTC13509BP) strain, a Lactobacillus paracasei KBL384 (accession number KCTC13510BP) strain or a Lactobacillus paracasei KBL385 (accession number KCTC13511BP) strain, a culture of the strain, It provides a pharmaceutical composition for the treatment or prevention of autoimmune diseases or inflammatory diseases containing an effective amount of at least one selected from the group consisting of the lysate of the strain and the extract of the strain.

[23] The present invention also provides a Lactobacillus paracasei KBL382 (accession number KCTC13509BP) strain, a Lactobacillus paracasei KBL384 (accession number KCTC13510BP) strain or Lactobacillus paracasei KBL385 (accession number KCTC13511BP) strain, a culture of the strain, It provides a method for treating bowel disease, comprising administering to an individual in need thereof at least one therapeutically effective amount selected from the group consisting of the lysate of the strain and the extract of the strain.

[24] The present invention also provides a Lactobacillus paracasei KBL382 (accession number KCTC13509BP) strain, a Lactobacillus paracasei KBL384 (accession number KCTC13510BP) strain or a Lactobacillus paracasei KBL385 (accession number KCTC13511BP) strain, a culture of the strain, It provides a method for treating an allergic disease comprising administering to an individual in need thereof at least one therapeutically effective amount selected from the group consisting of the lysate of the strain and the extract of the strain.

[25] The present invention also provides a Lactobacillus paracasei KBL382 (accession number KCTC13509BP) strain, a Lactobacillus paracasei KBL384 (accession number KCTC13510BP) strain or Lactobacillus paracasei KBL385 (accession number KCTC13511BP) strain, a culture of the strain, It provides a method of treating an autoimmune disease or an inflammatory disease comprising administering to an individual in need thereof at least one therapeutically effective amount selected from the group consisting of the lysate of the strain and the extract of the strain.

[26] The present invention also provides a Lactobacillus paracasei KBL382 (accession number KCTC13509BP) strain, Lactobacillus paracasei KBL384 (accession number KCTC13510BP) strain or Lactobacillus paracasei KBL385 (deposit No. KCTC13511BP) provides a composition comprising at least one selected from the group consisting of a strain, a culture of the strain, a lysate of the strain, and an extract of the strain.

[27] The present invention also provides a Lactobacillus paracasei KBL382 (accession number KCTC13509BP) strain, Lactobacillus paracasei KBL384 (accession number KCTC13510BP) strain or Lactobacillus paracasei KBL385 (deposited) for use in the prevention or treatment of allergic diseases. No. KCTC13511BP) provides a composition comprising at least one selected from the group consisting of a strain, a culture of the strain, a lysate of the strain, and an extract of the strain.

[28] The present invention also provides a Lactobacillus paracasei KBL382 (accession number KCTC13509BP) strain, Lactobacillus paracasei KBL384 (accession number KCTC13510BP) strain or Lactobacillus paraca for use in the prevention or treatment of autoimmune diseases or inflammatory diseases. J. KBL385 (accession number KCTC13511BP) provides a composition comprising at least one selected from the group consisting of a strain, a culture of the strain, a lysate of the strain, and an extract of the strain.

[29] The present invention also provides a Lactobacillus paracasei KBL382 (accession number KCTC13509BP) strain, a Lactobacillus paracasei KBL384 (accession number KCTC13510BP) strain or Lactobacillus paracasei KBL385 (accession number KCTC13510BP) for preparing a drug for preventing or treating intestinal diseases Accession No. KCTC13511BP) provides the use of a composition comprising at least one selected from the group consisting of a strain, a culture of the strain, a lysate of the strain, and an extract of the strain.

[30] The present invention also provides a Lactobacillus paracasei KBL382 (accession number KCTC13509BP) strain, Lactobacillus paracasei KBL384 (accession number KCTC13510BP) strain or Lactobacillus paracasei KBL385 (accession number KCTC13510BP) strain for preparing a drug for preventing or treating allergic diseases. Accession No. KCTC13511BP) provides the use of a composition comprising at least one selected from the group consisting of a strain, a culture of the strain, a lysate of the strain, and an extract of the strain.

[31] The present invention also provides a Lactobacillus paracasei KBL382 (accession number KCTC13509BP) strain, Lactobacillus paracasei KBL384 (accession number KCTC13510BP) strain or Lactobacillus para for preparing a drug for preventing or treating autoimmune diseases or inflammatory diseases. Casei KBL385 (accession number KCTC13511BP) provides the use of a composition comprising at least one selected from the group consisting of a strain, a culture of the strain, a lysate of the strain and an extract of the strain.

[32] Brief description of the drawing

[33] 1 is a result of confirming the inflammatory cytokine control effect of the KBL382 strain, KBL384 strain and KBL385 strain according to the present invention in PBMC.

[34] 2 is a result of confirming the effect of regulating T cell differentiation marker gene expression of the KBL382 strain, KBL384 strain, and KBL385 strain according to the present invention in PBMC.

[35] 3 shows cytokines (A) IL-2, (B) IFN-r, (C) according to the administration of the KBL382 strain, KBL384 strain and KBL385 strain according to the present invention in the PBMC cell line in which T cells were activated by the addition of anti-CD3 antibody ) IL-4, (D) IL-13, (E) IL-17A, and (F) IL-10 expression level changes were observed.

[36] Figure 4 is a KBL382 strain, KBL384 strain and KBL385 strain according to the present invention each administered to a mouse model induced enteritis, (A) body weight change, (B) colon length change, (C) colon length change and cecum This is the result of confirming the effect of reducing enteritis through weight change, (D) H&E staining of colon tissue and (E) change of MPO (myeloperoxidase) level of colon tissue.

[37] 5 is a result of observing the effect of strengthening the close junction of the KBL382 strain and the KBL385 strain according to the present invention as changes in expression levels of genes (A) ZO1, (B) Claudin3, (C) MUC4 involved in the intestinal wall tight junction.

[38] 6 is a result of comparing the commercially available antibody for treating enteritis infliximab and (A) the effect of improving colon length and (B) the effect of improving weight loss in order to confirm the effect of reducing enteritis of KBL382 strain according to the present invention.

[39] 7 is a (A) dermatitis score measurement, (B) itching alleviation effect, (C) skin thickness reduction effect according to administration of KBL382 strain in an atopic skin disease animal model in order to check the atopic relief effect of the KBL382 strain according to the present invention. (D) It is the result of observing the effect of reducing the IgE concentration in blood.

[40]

[41] Detailed description and preferred embodiments of the invention

[42] Unless otherwise defined, all technical and scientific terms used in this specification have the same meaning as commonly understood by an expert skilled in the art to which the present invention belongs. In general, the nomenclature used in this specification is well known and commonly used in the art.

[43]

[44] In the present invention, KBL382 (accession number KCTC13509BP), KBL384 (accession number KCTC13510BP) and KBL385 strains (accession number KCTC13511BP), which are Lactobacillus paracasei strains exhibiting excellent effects on immune regulation, were identified by confirming the immunomodulatory effect of human-derived microorganisms. It was confirmed, and as a result of analyzing the 16s rDNA of the strain, it was confirmed that the strain is a novel strain that has not been previously known.

[45]

[46] Therefore, in one aspect, the present invention relates to a novel probiotic Lactobacillus paracasei KBL382, Lactobacillus paracasei KBL384, or Lactobacillus paracasei KBL385 strain, wherein the strains are each of the following SEQ ID NOs: 1 to 3 Characterized in that it comprises a 16s rDNA sequence represented by.

[47]

[48]

[49]

[50] In the present invention, it was also confirmed that the KBL382, KBL384, and KBL385 strains have anti-inflammatory and immunomodulatory effects, respectively, as well as the effect of strengthening the close junction of the intestinal wall. It was confirmed that weight loss and colon length reduction were significantly improved by. In addition, among the above strains, KBL382 strain significantly improved the dermatitis score when administered to an animal model that caused atopic dermatitis, relieves itchiness, reduces skin thickness, and significantly improves the level of IgE in blood according to an allergic reaction. Confirmed.

[51]

[52] Accordingly, the present invention is a food or food containing an effective amount of at least one selected from the group consisting of the bacterial body of the KBL382, KBL384, or KBL385 strain, the culture of the strain, the lysate of the strain and the extract of the strain from another viewpoint It relates to a dragon composition.

[53] The composition for food or food addition may be easily utilized as a food effective in improving intestinal health or preventing intestinal disease, such as a main ingredient, an auxiliary ingredient, a food additive, a health functional food or a functional beverage, but is not limited thereto. Does not.

[54] The composition for food or food addition may also be easily utilized as a food for improving allergic symptoms, such as a main ingredient, an auxiliary ingredient, a food additive, a health functional food or a functional beverage, but is not limited thereto.

[55] In addition, the composition for food or food addition may also be easily utilized as a food for improving autoimmune diseases or inflammatory diseases, such as a main ingredient, an auxiliary ingredient, a food additive, a health functional food or a functional beverage, but limited to this It doesn't work.

[56] The food refers to a natural product or processed product containing one or more nutrients, and preferably refers to a state that can be eaten directly through a certain amount of processing process, and as a general meaning, food, food It refers to including all additives, health functional foods and functional beverages.

[57] Foods to which the composition for food according to the present invention can be added include, for example, various foods, beverages, gum, tea, vitamin complexes, and functional foods. In addition, foods in the present invention include special nutritional foods (e.g., formula, infants, baby food, etc.), processed meat products, fish meat products, tofu, muk, noodles (e.g., ramen, noodles, etc.), bread, health supplements, seasonings. Food (eg, soy sauce, miso, red pepper paste, mixed sauce, etc.), sauces, confectionery (eg, snacks), candy, chocolate, gum, ice cream, dairy products (eg fermented milk, cheese, etc.), other processed foods, kimchi, Pickled foods (various kimchi, pickles, etc.), beverages (eg, fruit drinks, vegetable drinks, soy milk, fermented drinks, etc.), natural seasonings (eg, ramen soup, etc.), but are not limited thereto. The food, beverage or food additive may be prepared by a conventional manufacturing method.

[58] The health functional food refers to a food group or food composition that has added value to act and express the function of the food using physical, biochemical, and biotechnological methods, etc. to the food, to control the biological defense rhythm of the food composition, to prevent and recover diseases, etc. It refers to food that is designed and processed to sufficiently express the body's regulatory function on the body. The functional food may contain food additives acceptable for food, and may further include suitable carriers, excipients, and diluents commonly used in the manufacture of functional foods.

[59] In the present invention, the functional beverage refers to a generic term for drinking to quench thirst or to enjoy the taste, and in addition to containing the composition for improving or preventing the symptoms of intestinal diseases as an essential component at the indicated ratio, there are special restrictions No, it may contain various flavoring agents or natural carbohydrates as additional ingredients, like a normal beverage.

[60] Further, in addition to those described above, the food containing the food composition for improving or preventing bowel disease symptoms of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavors and natural flavoring agents, coloring agents And fillers (cheese, chocolate, etc.), pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonates used in carbonated beverages, etc. And the above components may be used independently or in combination.

[61] In the food containing the food composition of the present invention, the amount of the composition according to the present invention may be included in 0.001% to 100% by weight of the total food weight, preferably 1% to 99% by weight. In the case of a beverage, it may be included in a ratio of 0.001g to 10g, preferably 0.01g to 1g based on 100ml, but in the case of long-term intake for the purpose of health and hygiene or for the purpose of health control May be less than the above range, and the active ingredient is not limited to the above range because it may be used in an amount greater than the above range because there is no problem in terms of safety.

[62] The food composition of the present invention may be prepared in the form of a composition suitable for human or animal consumption by adding the KBL382, KBL384, or KBL385 strain independently or to an acceptable carrier. That is, it can be added and used in foods that do not contain other probiotic bacteria and foods that already contain several probiotic bacteria. For example, in preparing the food of the present invention, other microorganisms that can be used with the strain of the present invention are suitable for human or animal ingestion, and when ingested, they can inhibit pathogenic harmful bacteria or improve the balance of microorganisms in the intestine of a mammal. These are those having probiotic activity, and are not particularly limited. An example of such a probiotic microorganism is Saccharomyces in MRS ( Saccharomyces ), Candida ( Candida ), blood teeth ( Pichia ) and sat rulrop sheath ( Torulopsis yeast (yeast), Aspergillus (including) Aspergillus ), Rhizopus Perth ( Fungi such as Rhizopus , Mucor , Penicillium , etc. and Lactobacillus), Bifidobacterium ( Bifidobacterium ), current Kono Stock ( Leuconostoc ), Lactococcus ( Lactococcus ), Bacillus ( Bacillus ), Streptococcus ( Streptococcus ), thereby Peony tumefaciens ( Propionibacterium ), Enterococcus ( Enterococcus ), Peddie O Rhodococcus ( Pediococcus is the bacterium belonging to the genus, etc.). Specific examples of suitable probiotic microorganisms include Saccharomyces cerevisiae , Bacillus coagulans , Bacillus licheniformis , Bacillus subtilis , and Bifidobak. Te Solarium BP Doom ( Bifidobacterium bifidum ), Bifidobacterium Infante Tees ( Bifidobacterium infantis ), Bifidobacterium rongeom ( Bifidobacterium longum ), Enterococcus passive help ( Enterococcus faecium ), Enterococcus faecalis ( Enterococcus faecalis ), Lactobacillus ash also filler's ( Lactobacillus acidophilus ), Lactobacillus Ali menta Aquarius ( Lactobacillus Alimentarius ), Lactobacillus Kasei ( Lactobacillus casei ), Lactobacillus Pico Yerba tooth ( Lactobacillus curvatus ), Lactobacillus del Brew key ( Lactobacillus delbruckii ), Lactobacillus Jones you ( Lactobacillus johnsonii ), Lactobacillus Pacifico US Taunus ( Lactobacillus farciminus ), Lactobacillus biasing Li ( Lactobacillus gasseri ), Lactobacillus helveticus ( Lactobacillus helveticus ), Lactobacillus ramno Seuss ( Lactobacillus rhamnosus ), Lactobacillus ruteri ( Lactobacillus reuteri ), Lactobacillus four K ( Lactobacillus sakei ), Lactococcus lactis ( Lactococcus lactis ), Peddie Oh Caucus during her CD rakti ( Pediococcus acidilactici ) And the like. Preferably, it is possible to further enhance the effect by further including a mixture of probiotic microorganisms having excellent probiotic activity and excellent immune activity enhancing effect in the food composition of the present invention. Examples of carriers that can be used in the food composition of the present invention may be extenders, high fiber additives, encapsulating agents, lipids, and the like, and examples of such carriers are well known in the art. The Lactobacillus paracasei strain of the present invention may be lyophilized or encapsulated, or in the form of a culture suspension or dry powder.

[63]

[64] The composition of the present invention may also be provided in the form of an animal feed additive containing the strain or an animal feed containing the same.

[65] The animal feed additive of the present invention may be in the form of a dry or liquid formulation, and may further contain other non-pathogenic microorganisms in addition to the KBL382, KBL384 or KBL385 strains. Microorganisms that can be added include, for example, Bacillus subtilis , which can produce proteases, lipolytic enzymes and sugar converting enzymes, lactose, which have physiological activity and organic decomposition under anaerobic conditions such as the stomach of cattle. Bacillus ( Lactobacillus ) strain, a fungus such as Aspergillus oryzae (Slyter, LL J. Animal Sci . 43.910-926) and Saccharomyces cerevisiae (Johnson, D. E et al. J. Anim. Sci ., 1983, 56, 735-739; Williams, PEV et al, 1990, 211) and the like can be used.

[66] The animal feed additive of the present invention may further include one or more enzyme preparations in addition to the Lactobacillus paracasei KBL382, Lactobacillus paracasei KBL384, or Lactobacillus paracasei KBL385 strain. Enzyme preparations added can be either dry or liquid, and enzyme preparations include lipolytic enzymes such as lipase, phytase, which degrades phytic acid to make phosphate and inositol phosphate, starch and Amylase, an enzyme that hydrolyzes α-1,4-glycoside bonds contained in glycogen, etc., phosphatase, an enzyme that hydrolyzes organophosphate, and cellulose Carboxymethylcellulase, xylase, which degrades xylose, maltase and saccha, which hydrolyze maltose into two molecules of glucose Sugar-generating enzymes, such as invertase, which hydrolyze saccharose to make a glucose-fructose mixture, may be used.

[67] Lactobacillus paracasei KBL382, Lactobacillus paracasei KBL384, or Lactobacillus paracasei KBL385 strain of the present invention is used as an additive for animal feed, and as feed raw materials, peanuts, peas, and candy including various grains and soybean proteins Radish, pulp, grain by-products, animal visceral powder and fish meal powder, etc. may be used, and these may be used unprocessed or processed without limitation. The processing process is not necessarily limited to this, for example, a process in which feed raw materials are filled and compressed to a certain outlet under pressure.In the case of proteins, extrusion molding is used to increase availability due to denaturation. It is desirable. Extrusion molding (extrusion) has advantages such as denaturing proteins and destroying anti-enzyme factors through heat treatment. In addition, in the case of soybean protein, the digestibility of the protein is improved through extrusion molding, and anti-nutritional factors such as trypsin inhibitor, one of the inhibitors of protease present in soybean, are inactivated. It can increase the nutritional value of soy protein by increasing the digestibility improvement.

[68]

[69] In another aspect, the present invention is composed of cells of the Lactobacillus paracasei KBL382, Lactobacillus paracasei KBL384, or Lactobacillus paracasei KBL385 strain, a culture of the strain, a lysate of the strain, and an extract of the strain. It relates to a pharmaceutical composition for the treatment or prevention of intestinal diseases containing an effective amount of at least one selected from the group.

[70] In another aspect, the present invention is composed of cells of Lactobacillus paracasei KBL382, Lactobacillus paracasei KBL384, or Lactobacillus paracasei KBL385 strain, a culture of the strain, a lysate of the strain, and an extract of the strain. It relates to a pharmaceutical composition for the treatment or prevention of allergic diseases containing an effective amount of at least one selected from the group.

[71] In another aspect, the present invention is composed of cells of Lactobacillus paracasei KBL382, Lactobacillus paracasei KBL384, or Lactobacillus paracasei KBL385 strain, a culture of the strain, a lysate of the strain, and an extract of the strain. It relates to a pharmaceutical composition for the treatment or prevention of autoimmune diseases or inflammatory diseases containing an effective amount of at least one selected from the group.

[72] The pharmaceutical composition of the present invention may be provided as a composition capable of being combined with live cells, in the form of a dry strain, a culture of the strain, a lysate of the strain, or a pharmaceutically acceptable carrier or medium thereof. Carriers or media used include solvents, dispersants, coatings, absorption accelerators, controlled release agents (i.e., sustained release agents), and one or more inert excipients (starch, polyol, granules, microfine cellulose, microcrystalline cellulose). (E.g., including cellpiers, Celphere beads, diluents, lubricants, binders, disintegrants, etc.), etc. If necessary, tablet formulations of the disclosed compositions may be standard aqueous or standard aqueous or tablet formulations. Excipients for use as pharmaceutically acceptable carriers and pharmaceutically acceptable inert carriers and examples of such additional components include binders, fillers, disintegrants, lubricants, antimicrobial agents. And a coating agent, but is not limited thereto.

[73] In the present invention, the intestinal disease is in the group consisting of abdominal bloating, abdominal discomfort, infectious diarrhea caused by pathogenic microorganisms, gastroenteritis, inflammatory bowel disease, neurogenic enteritis syndrome, irritable bowel syndrome, small intestine microbial hyperplasia, and intestinal acute diarrhea. It may be characterized as being selected, and includes diseases caused by impairment of the normal barrier function of the intestine.

[74] Inflammatory bowel disease (IBD) includes Crohn's disease, bowel lesions accompanying Behcet's disease, ulcerative colitis, hemorrhagic rectal ulcer and ileal cystitis, and refers to a group of diseases including Crohn's disease and ulcerative colitis. Ulcerative colitis only affects the large intestine. Inflammation and ulcers in ulcerative colitis are limited to the innermost two of the four layers of the large intestine, the mucosa and submucosa. In Crohn's disease, inflammation and ulcers can extend through all layers of the intestine in both the small and large intestine.

[75] On the other hand, irritable bowel syndrome is a chronic disease accompanied by changes in bowel habits such as diarrhea and constipation, along with abdominal discomfort such as abdominal discomfort and abdominal pain that are repeated for a long time without an organic cause. It is also exacerbated by the social environment that it does.

[76] In the present invention, allergic diseases include, but are not limited to, atopic dermatitis, dammargin, allergic rhinitis, allergic conjunctivitis, asthma, food allergy, anaphylactic shock, and the like.

[77] In the present invention, the autoimmune diseases are rheumatoid arthritis, lupus, systemic scleroderma, atopic dermatitis, psoriasis, psoriatic arthritis, asthma, Guilian-Barre syndrome, myasthenia gravis, dermatitis, multiple myositis, multiple sclerosis. , Autoimmune encephalomyelitis, polyarteritis nodosa, Hashimoto's thyroiditis, multiple sclerosis, temporal arteritis, childhood diabetes, alopecia areata, pemphigus, endophthalmitis, autoimmune hemolytic anemia, Wegener's granulomatosis, Sjogren's syndrome, Addison's disease, Crohn's disease, Behcet's disease It may include, but is not limited thereto.

[78] In addition, in the present invention, the inflammatory disease is a generic term for diseases whose main lesion is inflammation, and includes edema, conjunctivitis, periodontitis, rhinitis, otitis media, chronic sinusitis, sore throat, tonsillitis, bronchitis, pneumonia, gastric ulcer, gastritis, colitis, Gout, eczema, acne, atopic dermatitis, contact dermatitis, seborrheic dermatitis, ankylosing myelitis, rheumatic fever, fibromyalgia, osteoarthritis, psoriatic arthritis, rheumatoid arthritis, peri-shoulderitis, tendinitis , Tendonitis myositis, hepatitis, cystitis, nephritis, Sjogren's syndrome, myasthenia gravis, sepsis, vasculitis, bursitis, temporal arteritis, multiple sclerosis, and the like, but is not limited thereto.

[79] It is known that autoimmune diseases can be prevented or treated due to activation of regulatory T cells (Treg) or differentiation into T cells. Regulatory T cells are a type of CD4+ T cells that regulate the immune system and maintain tolerance to autoantigens to control autoimmune diseases. A transcription factor called Foxp3 is specifically involved in the development, maintenance and function of regulatory T cells, which regulates the immune response through the secretion of the immune suppressing cytokines IL-10 and TGF-β.

[80] In addition, it is known that when the differentiation rate of T cells into Th1 cells, Th2 cells, and Th17 cells is low and the differentiation rate of T cells into Treg cells is high, the inflammatory response can be effectively suppressed.

[81] Th1 cells, Th2 cells and Th17 cells differentiated from splenic T cells are known to be associated with the expression of the following transcription factors and cytokines, respectively: For Th1 cells, T-bet, IFN-γ and IL-12; For Th2 cells, GATA3 and IL-5; For Th17 cells, RORγIL-17.

[82]

[83] The effect of improving, treating or preventing an autoimmune disease or inflammatory disease exerted by the strain according to the present invention may be characterized by being induced by any one or more of the following mechanisms:

[84] i) the expression of any one or more selected from the group consisting of inflammatory cytokines IL-6, TNF, IL-1b, IL-8, IL-2, IFN-γ, IL-4, IL-13, IL-17A, or Inhibit secretion;

[85] ii) enhancing the expression or secretion of IL-10, an anti-inflammatory and immunomodulatory cytokine; And

[86] iii) Enhance the expression of Tregs involved in anti-inflammatory activity and immune regulation.

[87]

[88] The term'treating', unless stated otherwise, refers to reversing, alleviating, inhibiting or preventing the disease or disease to which the term applies, or one or more symptoms of the disease or disease. The term'treatment' used in the present invention refers to an act of treating when'treating' is defined as above. Thus, the treatment or therapy of intestinal diseases, allergic diseases, autoimmune diseases or inflammatory diseases in mammals may include one or more of the following:

[89] (1) inhibiting the development of intestinal diseases, allergic diseases, autoimmune diseases or inflammatory diseases,

[90] (2) preventing the spread of intestinal diseases, allergic diseases, autoimmune diseases or inflammatory diseases,

[91] (3) Alleviate intestinal diseases, allergic diseases, autoimmune diseases or inflammatory diseases.

[92] (4) preventing recurrence of intestinal diseases, allergic diseases, autoimmune diseases or inflammatory diseases, and

[93] (5) Palliating symptoms of intestinal disease, allergic disease, autoimmune disease or inflammatory disease

[94]

[95] The composition for the prevention or treatment of intestinal diseases, allergic diseases, autoimmune diseases or inflammatory diseases according to the present invention comprises a pharmaceutically effective amount of Lactobacillus paracasei KBL382, Lactobacillus paracasei KBL384, or Lactobacillus paracasei KBL385. The strain may be included alone or one or more pharmaceutically acceptable carriers, excipients, or diluents may be included.

[96] In the present invention, the term "effective amount (or effective amount)" refers to an amount that is very sufficient to deliver the desired effect, but sufficiently small enough to prevent serious side effects within the scope of medical judgment. The amount of microorganisms administered into the body by the composition of the present invention can be appropriately adjusted in consideration of the route of administration and the object to be administered.

[97] The composition of the present invention may be administered to a subject one or more times daily. Unit dosage means physically separate units suitable for unit administration for human subjects and other mammals, each unit containing a suitable pharmaceutical carrier and containing a predetermined amount of the microorganism of the present invention exhibiting a therapeutic effect. . The dosage unit for oral administration of an adult patient preferably contains 0.001 g or more of the microorganism of the present invention, and the oral dosage of the composition of the present invention is 0.001 to 10 g, preferably 0.01 to 5 g at a time. The pharmaceutically effective amount of the microorganism of the present invention is 0.01 to 10 g / day. However, the dosage varies depending on the severity of the patient's intestinal disease and the microorganisms and auxiliary active ingredients used. In addition, the total daily dose can be divided into several times and administered continuously as needed. Accordingly, the above dosage range does not limit the scope of the present invention in any way.

[98] In addition, "pharmaceutically acceptable" as used herein refers to a composition that is physiologically acceptable and does not usually cause allergic reactions such as gastrointestinal disorders and dizziness or similar reactions when administered to humans.

[99] The compositions of the present invention may be formulated using methods known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal. The formulation may be in the form of a powder, granule, tablet, emulsion, syrup, aerosol, soft or hard gelatin capsule, sterile injectable solution, or sterile powder. In addition, the composition for preventing or treating intestinal diseases according to the present invention may be administered through various routes including oral, transdermal, subcutaneous, intravenous or intramuscular, and the dosage of the active ingredient is the route of administration, the patient's age, sex, It may be appropriately selected according to various factors such as body weight and patient severity, and the composition for preventing or treating gastrointestinal diseases according to the present invention is combined with a known compound having an effect of preventing, ameliorating or treating symptoms of intestinal diseases. Can be administered.

[100] The pharmaceutical composition of the present invention can be provided as an enteric-coated enteric preparation, especially as an oral unit dosage form. In the present specification, "enteric coating" is not decomposed by gastric acid, so that the coating is maintained, but in the small intestine it is sufficiently decomposed to allow the active ingredient to be released into the small intestine, including all kinds of known pharmaceutically acceptable coating do. The "enteric coating" of the present invention is maintained for 2 hours or more when artificial gastric juice such as a pH 1 HCl solution is brought into contact at 36° C. to 38° C., and preferably, artificial gastric juice such as a pH 6.8 KH2PO4 buffer It refers to a coating that decomposes within 30 minutes in intestinal juice.

[101] The enteric coating of the present invention is coated in an amount of about 16 to 30, preferably 16 to 20 or 25 mg or less to one core. When the thickness of the enteric coating of the present invention is 5 to 100 µm, preferably 20 to 80 µm, satisfactory results are obtained as an enteric coating. The material for the enteric coating is appropriately selected from known polymer materials. Suitable polymeric materials are described in a number of known literature (L. Lachman et al., The Theory and Practice of Industrial Pharmacy, 3rd ed., 1986, pp. 365-373; H. Sucker et al., Pharmazeutische Technologie, Thieme, 1991, pp. 355-359 ; Hagers Handbuchder pharmazeutischen Praxis, 4th ed., Vol. 7, pp. 739-742, and 766-778, (SpringerVerlag, 1971); And Remington's Pharmaceutical Sciences, 13th ed., pp. 1689-1691 (Mack Publ., Co. , 1970), and may include cellulose ester derivatives, cellulose ethers, methylacrylate copolymers of acrylic resins, and copolymers of maleic acid and phthalic acid derivatives.

[102] The enteric coating of the present invention can be prepared using a conventional enteric coating method in which an enteric coating solution is sprayed onto the core. Suitable solvents used in the enteric coating process include alcohols such as ethanol, ketones such as acetone, and halogenated hydrocarbon solvents such as dichloromethane (CH 2 Cl 2 ), and a mixed solvent of these solvents may be used. An emollient such as di(di)-n-butylphthalate or triacetin is added to the coating solution in a ratio of 1 to about 0.05 to about 0.3 (coating material to emollient). It is appropriate to carry out the spraying process continuously, and it is possible to adjust the spraying amount in consideration of the conditions of the coating. The spray pressure can be variously adjusted, and satisfactory results are obtained with spray pressures of generally about 1 to about 1.5 bar.

[103] In another aspect, the present invention provides the use of the strain or composition for use in the prevention or treatment of intestinal diseases, allergic diseases, autoimmune diseases or inflammatory diseases, and the preparation of therapeutic agents for intestinal diseases, allergic diseases, autoimmune diseases or inflammatory diseases. For the use of the strain or composition.

[104] Specifically, the present invention is a Lactobacillus paracasei KBL382 (accession number KCTC13509BP) strain, Lactobacillus paracasei KBL384 (accession number KCTC13510BP) strain or Lactobacillus paracasei KBL385 (accession number KCTC13510BP) for use in the prevention or treatment of intestinal diseases. Accession No. KCTC13511BP) It relates to a composition comprising at least one selected from the group consisting of a strain, a culture of the strain, a lysate of the strain, and an extract of the strain.

[105] The present invention also provides a Lactobacillus paracasei KBL382 (accession number KCTC13509BP) strain, Lactobacillus paracasei KBL384 (accession number KCTC13510BP) strain or Lactobacillus paracasei KBL385 (deposited) for use in the prevention or treatment of allergic diseases. No. KCTC13511BP) to a composition comprising at least one selected from the group consisting of a strain, a culture of the strain, a lysate of the strain, and an extract of the strain.

[106] The present invention also provides a Lactobacillus paracasei KBL382 (accession number KCTC13509BP) strain, Lactobacillus paracasei KBL384 (accession number KCTC13510BP) strain or Lactobacillus paraca for use in the prevention or treatment of autoimmune diseases or inflammatory diseases. It relates to a composition comprising at least one selected from the group consisting of the J. KBL385 (Accession No. KCTC13511BP) strain, a culture of the strain, a lysate of the strain, and an extract of the strain.

[107] The present invention also provides a Lactobacillus paracasei KBL382 (accession number KCTC13509BP) strain, a Lactobacillus paracasei KBL384 (accession number KCTC13510BP) strain or Lactobacillus paracasei KBL385 (accession number KCTC13510BP) for preparing a drug for preventing or treating intestinal diseases. Accession No. KCTC13511BP) relates to the use of a composition comprising at least one selected from the group consisting of a strain, a culture of the strain, a lysate of the strain, and an extract of the strain.

[108] The present invention also provides a Lactobacillus paracasei KBL382 (accession number KCTC13509BP) strain, Lactobacillus paracasei KBL384 (accession number KCTC13510BP) strain or Lactobacillus paracasei KBL385 (accession number KCTC13510BP) strain for preparing a drug for preventing or treating allergic diseases. Accession No. KCTC13511BP) relates to the use of a composition comprising at least one selected from the group consisting of a strain, a culture of the strain, a lysate of the strain, and an extract of the strain.

[109] The present invention also provides a Lactobacillus paracasei KBL382 (accession number KCTC13509BP) strain, Lactobacillus paracasei KBL384 (accession number KCTC13510BP) strain or Lactobacillus para for preparing a drug for preventing or treating autoimmune diseases or inflammatory diseases. It relates to the use of a composition comprising at least one selected from the group consisting of casei KBL385 (accession number KCTC13511BP) strain, a culture of the strain, a lysate of the strain, and an extract of the strain.

[110] In the present invention, the term'prevention' relates to averting, delaying, impeding, or hindering to reduce disease.

[111] In the present invention, the term'treatment' relates to caring for a subject suffering from a disease in order to ameliorate, cure or reduce the symptoms of the disease or reduce or stop the progression of the disease.

[112]

[113] In another aspect, the present invention uses a pharmaceutically effective amount of the strain or composition to prevent or treat intestinal diseases, allergic diseases, autoimmune diseases or inflammatory diseases, or to improve intestinal health, allergic reactions, immunity or inflammatory reaction It relates to a method for preventing or treating intestinal diseases, allergic diseases, autoimmune diseases or inflammatory diseases comprising the step of administering to.

[114] Specifically, the present invention is Lactobacillus paracasei KBL382 (accession number KCTC13509BP) strain, Lactobacillus paracasei KBL384 (accession number KCTC13510BP) strain or Lactobacillus paracasei KBL385 (accession number KCTC13511BP) strain, a culture of the strain, It relates to a method for treating bowel disease comprising administering to an individual in need thereof a therapeutically effective amount of at least one selected from the group consisting of the lysate of the strain and the extract of the strain.

[115] The present invention also provides a Lactobacillus paracasei KBL382 (accession number KCTC13509BP) strain, a Lactobacillus paracasei KBL384 (accession number KCTC13510BP) strain or a Lactobacillus paracasei KBL385 (accession number KCTC13511BP) strain, a culture of the strain, It relates to a method for treating an allergic disease comprising administering a therapeutically effective amount of at least one selected from the group consisting of the lysate of the strain and the extract of the strain to an individual in need thereof.

[116] The present invention also provides a Lactobacillus paracasei KBL382 (accession number KCTC13509BP) strain, a Lactobacillus paracasei KBL384 (accession number KCTC13510BP) strain or a Lactobacillus paracasei KBL385 (accession number KCTC13511BP) strain, a culture of the strain, It relates to a method for treating an autoimmune disease or an inflammatory disease comprising administering to an individual in need thereof a therapeutically effective amount of at least one selected from the group consisting of the lysate of the strain and the extract of the strain.

[117] Since the pharmaceutical composition and the administration method used for the prevention or treatment method of the intestinal disease, allergic disease, autoimmune disease or inflammatory disease have been described above, the common content between the two is to avoid excessive complexity of the present specification, The description is omitted.

[118] On the other hand, the individual to which the composition for the prevention or treatment of the intestinal disease, allergic disease, autoimmune disease or inflammatory disease can be administered includes all animals including humans. For example, it may be an animal such as a dog, cat, or mouse.

[119]

[120] Hereinafter, the present invention will be described in more detail through examples. These examples are for illustrative purposes only, and it will be apparent to those of ordinary skill in the art that the scope of the present invention is not construed as being limited by these examples.

[121]

[122] Example 1. Screening of probiotic strains having immunomodulatory function

[123] A probiotic strain having an immunomodulatory function was screened using the leukemia monocytes THP-1 cell line and peripheral blood monocytes (PBMC). In the two cell lines, strains derived from the human digestive tract (gut) or vagina (vagina), respectively, are dispensed in a ratio of 1:100 cell line:strain, and IL-6, a cytokine that is a major indicator of inflammation-induced response The ratio of IL-10, a cytokine, which is a major indicator of inflammation regulation, (IL-10 / IL-6), and the ratio of IL-10 to IFN-γ, a major indicator of an autoimmune response ( IL-10 / IFN-γ) was measured. For screening, Lactobacillus gasseri 2 types, Lactobacillus reuteri 1 type, Lactobacillus rhamnosus 5 types, Lactobacillus fermentum 2 types, Lactobacillus fermentum 2 types, ( Lactobacillus paracasei ) 4 species, Lactobacillus salivarius 4 species, Lactobacilus plantarum) 1 species, Lactobacillus acidophilus 2 species and Lactococcus lactis 2 species, a total of 23 strains were used.

[124] As a result of screening, the three strains of Lactobacillus paracasei KBL382, KBL384 and KBL385 showed the highest IL-10 / IL-6 values. In particular, among the three Lactobacillus paracasei strains, KBL382 had the highest IL-10 / IL-6 value of 2.22 in THP-1 cell line, and IL-10 / IFN-γ value of 9 in peripheral blood mononuclear cells with very high immunomodulatory effect. Is shown. Table 1 below shows the results of measuring the values ​​of IL-10 / IL-6 and IL-10 / IFN-γ of three Lactobacillus paracasei strains among 23 probiotic strains used in this screening. Accordingly, three strains of Lactobacillus paracasei KBL382, KBL384 and KBL385 were predicted to have a high effect on improving intestinal health, and additional experiments were conducted on these strains.

[125]

[126] [Table 1]

[127]

[128] Example 2.Lactobacillus paracasei KBL382, KBL384 and KBL385 strains of inflammatory cytokine expression and T cell differentiation control effect verification ( in vitro test)

[129] In the case of treating the Lactobacillus paracasei KBL382, KBL384 and KBL385 strains in the THP-1 cell line to verify the immunomodulatory effect by the Lactobacillus paracasei KBL382, KBL384 and KBL385 strains, the ability to generate cytokines involved in immune regulation And when the Lactobacillus paracasei KBL382 and KBL385 strains were treated on PBMC, it was confirmed whether or not the T cell marker gene expression was expressed.

[130] First, the THP-1 cell line was dispensed into each well of a 24-well plate by 1 to 10 5 cells, differentiated into mature macrophages, and then the culture solution was replaced. After 3 hours, the wells with LPS as positive control (positive control) to 1 μg / ml concentration of the other wells, the number of viable cells Lactobacillus casei para KBL382, KBL384 or KBL385 strains each Х 1 10 7Cell-by-cell treatment and after 24 hours elapsed, the culture solution was collected and the amount of each cytokine was measured using a BD Cytometric Bead Array (CBA) human inflammation kit (Cat No. 551811) according to the manufacturer's method. As a negative control (Cont), PBS buffer was treated and the same experimental procedure was performed. As a result, as shown in Figure 1, in the THP-1 cell line, the group treated with Lactobacillus paracasei KBL382 and KBL385 strains compared to the group treated with LPS, the inflammatory cytokines IL-6, TNF, IL-1b and IL- 8 was markedly low. When KBL384 strain was treated, IL-6 was found to be significantly lower than that of the LPS-treated experimental group, but there was no significant difference in TNF, IL-1b, and IL-8 compared to the LPS-treated group. In the case of IL-10, a significant increase or decrease was not observed in the group treated with the strains KBL382, KBL384, and KBL385 compared to the group treated with LPS, but it could be observed that the overall increase was induced compared to the negative control group. Therefore, it was concluded that Lactobacillus paracasei KBL382 and KBL385 strains had the effect of remarkably inhibiting the production of inflammatory cytokines in THP-1 cells, and a follow-up experiment was conducted to confirm the pattern of T cell differentiation.

[131] In order to confirm the effect of the KBL382 and KBL385 strains on T cell differentiation, PBMC cells were dispensed 5 Х 10 5 cells into each well of a 24-well plate, and then Lactobacillus paracasei KBL382 or KBL385 strains 5 Х 10 6 It was added cell by cell. Is E. coli (as a control E.coli to each well as a number of viable cells 0157 EC4115) based Х 10 5 6Each cell was added or LPS was added to a concentration of 500 ng / ml. E. coli is known to increase the expression of T-bet, GATA3, and RORrt genes, which are T cell effector cell markers related to inflammation-induced response, while LPS is known to increase the expression of FOXP3 gene, a marker of Treg cells related to inflammation regulation. have. The PBMC cell experimental group prepared under the above conditions was incubated for 5 days and then obtained and cells were collected. To check the amount of gene expression, RNA was first extracted using an easy-spin (DNA free) Total RNA Extraction Kit (Intron), and then cDNA was synthesized with a High Capacity RNA-to-cDNA Kit (ThermoFisher). The synthesized cDNA was subjected to real-time PCR using the Rotor-Gene® Q (Qiagen) equipment according to the manufacturer's method with the Rotor-Gene SYBR Green PCR kit (Qiagen), and T- Expression of bet and Th2 marker genes GATA3, Th17 marker genes RORrt, and Immune regulatory T cells (Treg cells) marker gene FOXP3 mRNA expression were measured. At this time, the amount of expression of the B2M gene was measured as an internal control to correct the relative amount of gene expression between each experimental group. The base sequence of the primer used to confirm the expression of each gene is as follows.

[132]

[133] B2M

[134] Forward: 5'-CCA GCA GAG AAT GGA AAG TC-3'' (SEQ ID NO: 4)

[135] Reverse: 5′-GAT GCT TCT TAC ATG TCT CG-3′ (SEQ ID NO: 5)

[136]

[137] T-bet

[138] Forward: 5'-CCC CAA GGA ATT GAC AGT TG-3' (SEQ ID NO: 6)

[139] Reverse) 5′-GGG AAA CTA AAG CTC ACA AAC-3′ (SEQ ID NO: 7)

[140]

[141] GATA3

[142] Forward: 5'-CTG CAA TGC CTG TGG GCT C-3' (SEQ ID NO: 8)

[143] Reverse: 5′-GAC TGC AGG GAC TCT CGC T-3′ (SEQ ID NO: 9)

[144]

[145] RORrt

[146] Forward: 5'-AAG ACT CAT CGC CAA AGC AT-3' (SEQ ID NO: 10)

[147] Reverse: 5'-TCC ACA TGC TGG CTA CAC A-3' (SEQ ID NO: 11)

[148]

[149] FOXP3

[150] Forward: 5'-TCA AGC ACT GCC AGG CG-3' (SEQ ID NO: 12)

[151] Reverse: 5′-CAG GAG CCC TTG TCG GAT-3′ (SEQ ID NO: 13)

[152]

[153] As a result, as shown in Figure 2, Lactobacillus paracasei KBL382 and KBL385 strains compared to Escherichia coli, while the expression levels of T-bet, GATA3, and RORrt genes, which are effector cell markers of inflammatory T cells, were significantly lowered, while LPS Similarly, it was confirmed that the mRNA of FOXP3, a marker of Treg cells for maintaining immune homeostasis, was significantly increased.

[154]

[155] Example 3. Lactobacillus paracasei KBL382, KBL384 and KBL385 T cell immunomodulatory effect verification of strains ( in vitro test)

[156] On the other hand, in order to verify the immunomodulatory effect of T cells by Lactobacillus paracasei KBL382, KBL384 and KBL385 strains, T cells are activated in PBMC cells, and then the paracasei KBL382, KBL384 and KBL385 strains are treated respectively. , It was confirmed the expression level of inflammatory cytokines.

[157] PBMC cells with anti-CD3 antibody (1 μg / ml, ebioscience) that activate T cells were dispensed into each well of a 96-well plate by 2 x 10 5 cells, and then Lactobacillus paracasei KBL382, KBL384 or KBL385 strain Based on the number of viable cells, 1 Х 10 7 cells were added (bacteria:PBMC = 50:1). As a control, Escherichia coli K12 (ATCC 10798) was added to each well by 1 Х 10 7 cells based on the number of viable cells. After incubating the experimental group of T cells-activated PBMC cells prepared under the above conditions for 3 days, collect the supernatant and use the BD cytometric Bead Array (CBA) human inflammation kit (Cat No. 551811) for each cytokine according to the manufacturer's method. The amount was measured.

[158] As a result, as shown in FIG. 3, in PBMC cell lines in which T cells were activated by addition of anti-CD3 antibody, Lactobacillus paracasei KBL382, KBL384, and KBL385 strains were all Th1 cytokines IL-2 and IFNγ, Th2 cytokines. The expression of IL-4 and IL-13, and IL-17A, a cytokine of Th17, was significantly reduced compared to the experimental group treated with E. coli and PBS alone, whereas the anti-inflammatory cytokine IL-10 was observed in the experiment. It was confirmed that the three Lactobacillus paracasei strains used were significantly increased compared to the experimental group treated with PBS alone, of which KBL382 strain significantly increased compared to the E. coli added group. When these experimental results were synthesized, it was concluded that Lactobacillus paracasei KBL382, KBL384 and KBL385 strains significantly reduced T cell inflammatory cytokines and increased anti-inflammatory cytokines.

[159]

[160] Example 4. Lactobacillus paracasei KBL382, KBL384, and KBL385 strains of alleviating enteritis effect verification ( in vivo test)

[161] It was attempted to confirm whether the Lactobacillus paracasei KBL382, KBL384 and KBL385 strains exhibited the effect of improving intestinal function in vivo . To this end, after dividing C57BL / 6 mice into groups of 10 mice each, 2% DSS was dissolved in tap water and drunk with drinking water for 9 days to induce enteritis. At the same time, 200 μl of PBS was orally administered to control mice every day, and 200 μl of Lactobacillus paracasei KBL382, KBL384, or KBL385 strains were diluted in PBS to 2 Х 10 10 CFU / ml , respectively , and then orally 200 μl each day. It was administered so that the daily dose was 4 Х 10 9 CFU. Thereafter, for 9 days in which gastroenteritis was induced by supplying DSS, the change in body weight of the control and experimental mice was measured daily, and on the 9th day after supplying DSS, the mice were autopsied to measure the length of the colon.

[162] As a result, as shown in Figure 4, in weight change, all three strain-treated groups of KBL382, KBL384, and KBL385 showed a significant weight loss improvement effect compared to the control mice that were not treated with anything. In all strains, it was confirmed that the width of the reduction in colon length was significantly improved compared to the control mice.

[163] In addition, H&E staining was performed to measure the degree of inflammation in the experimental groups of KBL382 and KBL385 strains, and Myeloperoxidase (MPO) levels were measured in the tissues. After autopsy, in order to examine the lesions of the colon by H&E staining, the distal part of the colon was fixed in 10% neutral formalin solution. Paraffin tissue specimens were sectioned with a thickness of 5 μm, stained with hematoxylin & eosin, and observed with an optical microscope. In addition, for MPO measurement, first, colon tissue was put in RIPA buffer to which protease inhibitor was added, and the tissue was disrupted with a homogenizer. After centrifuging the crushed tissue at 4° C. at 15,000 Х g for 10 minutes, MPO was measured using the supernatant according to the protocol of ELISA kit (Hycult Biotech, MPO, Mouse, cat. HK210-02).

[164] As a result, as shown in Figure 4, it was confirmed that the inflammation was alleviated in both the experimental groups to which the two strains were administered KBL382 and KBL385 compared to the control group. I could see it. The effect of strengthening the intestinal wall close junction was confirmed using the colon tissue obtained here.

[165]

[166] Example 5. Lactobacillus paracasei KBL382 and KBL385 strengthen the intestinal wall tight junction

[167] In order to confirm the effect of enhancing the intestinal wall adhesion junction of Lactobacillus paracasei KBL382 and KBL385 strains, the mRNA expression levels of genes involved in the intestinal wall adhesion junction in the cells isolated from the mouse colon tissue isolated in Example 4 were measured. To check the amount of gene expression, RNA was first extracted from the tissue using the easy-spin (DNA free) Total RNA Extraction Kit (Intron), and then cDNA was synthesized with the High Capacity RNA-to-cDNA Kit (ThermoFisher). MRNA expression of zonula occluden-1 (ZO-1), Claudin3 and MUC-4 , in vivo intestinal wall adhesion marker proteins with Rotor-Gene® Q (Qiagen) using the Roter-gene SYBR green PCR kit (Qiagen) Was measured. The expression level of the hypoxanthine-guanine phosphoribosyltransferase (HPRT) gene was measured as a control for correcting the relative gene expression level between each experimental group. Primers for measuring gene expression were made to have sequences capable of specific binding to each gene as follows.

[168]

[169] Zo-1

[170] Fw: 5'-ACC CGA AAC TGA TGC TGT GGA TAG-3' (SEQ ID NO: 14)

[171] Rw: 5'-AAA TGG CCG GGC AGA ACT TGT GTA-3' (SEQ ID NO: 15)

[172]

[173] Claudin3

[174] Fw: 5'-CAG ACG TCC GTC AGT TTT CG-3' (SEQ ID NO: 16)

[175] Rw: 5'-CAT GGC TGC TGG ACT TGA AC-3' (SEQ ID NO: 17)

[176]

[177] MUC-4

[178] Fw: 5'-GTC TCC CAT CAC GGT TCA GT-3' (SEQ ID NO: 18)

[179] Rw: 5'-TGT CAT TCC ACA CTC CCA GA-3' (SEQ ID NO: 19)

[180]

[181] HPRT

[182] Fw: 5'-TTA TGG ACA GGA CTG AAA GAC-3'' (SEQ ID NO: 20)

[183] Rw: 5′-GCT TTA ATG TAA TCC AGC AGG T-3′′ (SEQ ID NO: 21)

[184]

[185] As a result, as shown in FIG. 5, it was confirmed that the expression levels of the three genes measured in the mice administered with the KBL382 and KBL385 strains were increased compared to the control group administered with only PBS, thereby recovering the intestinal wall tight junction, thus making the strain inflammatory It was found that it can be used for treatment purposes such as bowel disease and irritable bowel syndrome.

[186]

[187] Example 6. Comparison of enteritis relief effect between antibody for treating enteritis and KBL382

[188] Infliximab (product name Remicade) is a therapeutic recombinant antibody drug used in the form of an injection for autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, Crohn's disease in adults, Crohn's disease in children, psoriasis, and psoriatic arthritis. The purpose of this study was to determine how the KBL382 strain and infliximab showed differences in the effect of improving bowel disease symptoms in vivo .

[189] For the comparison of the effects, after dividing C57BL / 6 mice into groups of 8 mice each, 2% DSS was dissolved in tap water and then drunk with drinking water for 9 days to induce enteritis. At the same time, the control group mice were administered orally each day 200 μl of PBS, the experimental group mice 2 Х 10 to KBL382 strains in PBS 10 4 Х 10 amount was daily dosage by oral administration per day 200 μl and then diluted to the CFU / ml 9 CFU Was made to be. Infliximab antibody was administered to the therapeutic antibody administration group once on the third day so that the dose was 5 mg / kg per mouse.

[190] Thereafter, for 9 days in which gastroenteritis was induced by supplying DSS, the change in body weight of the control and experimental mice was measured daily, and on the 9th day after supplying DSS, the mice were autopsied to measure the length of the colon.

[191] As a result, as shown in FIG. 6(A), it was confirmed that in the change in colon length, in the KBL382 strain-treated group and infliximab-administered group, the bowel length reduction width was significantly improved compared to the control mice. Compared to the infliximab administration group, the effect of improving the colon length of the KBL382 strain-treated group was similar or rather high.

[192] In the body weight change, as shown in Fig. 6(B), the KBL382 strain-treated group and the infliximab-administered group showed a significant improvement in weight loss compared to the control mice not treated with anything. The alleviation effect of initial weight loss until 5 days after administration was found to be superior in the infliximab-treated group compared to the KBL382 strain-treated group, but after that, the improving effect of infliximab decreased, while the weight loss of the 382 strain-treated group. As the effect increased, it was confirmed that the effect between administration groups gradually became similar until the 9th day. Therefore, in using the strain for the treatment of inflammatory bowel disease and irritable bowel syndrome, it was confirmed that a therapeutic effect similar to that of commercially available therapeutic antibodies can be expected.

[193]

[194] Example 7. Atopy alleviation effect of KBL382

[195] To confirm the atopic alleviation effect of KBL382 strain, an NC / Nga mouse model, an animal model of atopic skin disease, was used.

[196] After grouping 9 NC / Nga mice for each group, the back of the mouse was removed from the lower part of the ear to the upper part of the tail, and left for 24 hours. After that, an ointment containing Dermatophagoides farinae extract (DFE: Dermatophagoides farinae extract), which is a house dust mites (HDM) antigen, is applied to the epilation site once or twice a week so that 100 mg of DFE per head is treated for 7 weeks. It caused atopic dermatitis. From the third week of dermatitis induction, 200 μl of PBS was orally administered to the control mice daily, and the experimental mice were diluted with KBL382 strain and Lactobacillus rhamnosus KBL365 strain in 200 μl PBS to a minimum of 1 Х 10 9 CFU per animal , and then daily. 200 μl was administered orally. Thereafter, for 4 weeks of administration of the bacteria, the dermatitis scores of the control and experimental mice were measured weekly, and the scratching time and skin thickness of the mice and the mouse were autopsied on the 4th week after administration of the bacteria. Thus, the IgE concentration in the blood was measured.

[197]

[198] 7-1. Measurement of dermatitis score

[199] For the evaluation of DFE-induced skin lesions, the dermatitis score was measured through the following method. Skin conditions were investigated by taking photos for 4 weeks at 1-week intervals from the 3rd week of administration of the strain. Check the four indicators of skin dryness, edema, redness and bleeding (erythema / hemorrhage), and erosion / excoriation to determine a lesion-free state (none) and a mild state. 1 point (mild), the middle condition was given 2 points (moderate), the severe condition was given 3 points (severe), and the total score was evaluated.

[200] As a result, as can be seen in Figure 7 (A), it was confirmed that the dermatitis score was significantly reduced in the bacteria administered with the KBL382 strain compared to the control group (Negative) in which atopic dermatitis was induced and the group administered with the KBL365 strain. Thus, it was possible to confirm the relief of the atopic dermatitis score according to the intake of the KBL382 strain.

[201]

[202] 7-2. Itching relief effect

[203] In order to confirm the itch relief effect of the administration of KBL382 strain in a DFE-induced atopic dermatitis mouse model, the number of scratches of the mouse was measured for 10 minutes after 4 weeks of administration of the strain.

[204] As a result, as can be seen in Fig. 7(B), the number of scratches in the experimental group to which the KBL382 strain was administered was significantly reduced compared to the PBS-administered group, and it was confirmed that the itching symptoms of atopic dermatitis were alleviated by ingestion of the KBL382 strain. there was.

[205]

[206] 7-3. Reduction in skin thickness

[207] To confirm the effect of increasing the thickness of the skin according to the administration of the KBL382 strain in a mouse model of DFE-induced atopic dermatitis, 4 weeks after the administration of the strain, the thickness of the ear and back skin of the mouse was measured using a calipers and atopic Relief of edema symptoms due to dermatitis was observed. As a result, as can be seen in Figure 7 (C), it was observed the effect of significantly reducing the thickness of the ear and skin compared to the control group and the KBL365 strain administration group in the experimental group to which the KBL382 strain was administered.

[208]

[209] 7-4. Decrease in blood IgE concentration

[210] In most patients with atopic dermatitis, the IgE concentration was found to increase as the clinical severity of atopic dermatitis increased (Matsumoto M, J Immunol. 1999). Therefore, the concentration of IgE, a representative hematologic factor in the occurrence of atopic dermatitis, was collected 3 weeks after strain administration, blood was collected, plasma was isolated, and measured using Mouse IgE ELISA Set (Cat No. 555248, BD OptEIA). As a result, as shown in FIG. 7(D), it was found that the concentration of IgE in the blood was significantly reduced in the experimental group to which the KBL382 strain was administered orally, and the effect of treating atopic dermatitis according to the intake of the KBL382 strain was confirmed.

[211]

[212] As described above, specific parts of the present invention have been described in detail, and for those of ordinary skill in the art, it is obvious that these specific techniques are only preferred embodiments, and the scope of the present invention is not limited thereby. something to do. Therefore, it will be said that the practical scope of the present invention is defined by the appended claims and their equivalents.

[213]

[214] Name of deposit institution: Korea Research Institute of Bioscience and Biotechnology

[215] Accession number: KCTC13509BP

[216] Consignment Date: 20180417

[217]

[218] Name of deposit institution: Korea Research Institute of Bioscience and Biotechnology

[219] Accession number: KCTC13510BP

[220] Consignment Date: 20180417

[221]

[222] Name of deposit institution: Korea Research Institute of Bioscience and Biotechnology

[223] Accession number: KCTC13511BP

[224] Consignment Date: 20180417

[225] Industrial availability

[226] Lactobacillus paracasei KBL382 (accession number KCTC13509BP) strain, Lactobacillus paracasei KBL384 (accession number KCTC13510BP) strain and Lactobacillus paracasei KBL385 (accession number KCTC13511BP) strain according to the present invention have anti-inflammatory activity and immunomodulatory function This is excellent, and the reinforcing effect of the intestinal wall close junction is excellent, and it exhibits the effect of treating enteritis by suppressing the decrease in weight loss and the length of the colon caused by enteritis, weakening the allergic reaction of cells, and symptomatic By remarkably improving allergic diseases. Therefore, with one strain, it can achieve all of the objectives for anti-inflammatory effect, immunomodulatory effect, improvement of intestinal health function, and allergic disease, and thus can be usefully used as a probiotic material.

[227]

[228] Attached electronic file.

[229]

[230]

[231]

Claims

Claims

1. Lactobacillus paracasei KBL382 (accession number KCTC13509BP) strain.

2. The strain according to claim 1, wherein the strain has a 16s rDNA sequence represented by SEQ ID NO: 1.

3. Lactobacillus paracasei KBL384 (accession number KCTC13510BP) strain.

4. The strain according to claim 3, wherein the strain has a 16s rDNA sequence represented by SEQ ID NO: 2.

5. Lactobacillus paracasei KBL385 (accession number KCTC13511BP) strain.

6. The strain according to claim 5, wherein the strain has a 16s rDNA sequence represented by SEQ ID NO: 3.

7. A food composition containing an effective amount of at least one selected from the group consisting of the strain of any one of claims 1 to 6, the culture of the strain, the lysate of the strain, and the extract of the strain.

8. A composition for food addition containing an effective amount of at least one selected from the group consisting of the strain of any one of claims 1 to 6, the culture of the strain, the lysate of the strain, and the extract of the strain.

9. The composition of claim 7, wherein the composition is a health functional food composition for improving intestinal health.

10. Pharmaceutical for the treatment or prevention of intestinal diseases containing an effective amount of at least one selected from the group consisting of the strain of any one of claims 1 to 6, the culture of the strain, the lysate of the strain, and the extract of the strain. Composition.

11. According to claim 10, The intestinal disease is a group consisting of abdominal bloating, abdominal discomfort, infectious diarrhea caused by pathogenic microorganisms, gastroenteritis, inflammatory bowel disease, neurogenic enteritis syndrome, irritable bowel syndrome, small intestine microbial hyperplasia, and intestinal acute diarrhea. Composition, characterized in that selected from.

12. The composition of claim 7, wherein the composition is a health functional food composition for improving allergy symptoms.

13. A pharmaceutical for the treatment or prevention of allergic diseases containing an effective amount of at least one selected from the group consisting of the strain of any one of claims 1 to 6, the culture of the strain, the lysate of the strain, and the extract of the strain. Composition.

14. 14. The pharmaceutical composition according to claim 13, wherein the allergic disease is atopic dermatitis, dammajin, allergic rhinitis, allergic conjunctivitis, asthma, food allergy or anaphylactic shock.

15. The composition of claim 7, wherein the composition is a health functional food composition for improving autoimmune diseases or inflammatory diseases.

16. The treatment or prevention of autoimmune diseases or inflammatory diseases containing an effective amount of at least one selected from the group consisting of the strain of any one of claims 1 to 6, the culture of the strain, the lysate of the strain, and the extract of the strain. Pharmaceutical composition for.

17. The step of administering to an individual in need thereof at least one therapeutically effective amount selected from the group consisting of the strain of any one of claims 1 to 6, the culture of the strain, the lysate of the strain, and the extract of the strain. Intestinal disease treatment method comprising a.

18. The step of administering to an individual in need thereof at least one therapeutically effective amount selected from the group consisting of the strain of any one of claims 1 to 6, the culture of the strain, the lysate of the strain, and the extract of the strain. Allergic disease treatment method comprising a.

19. The step of administering to an individual in need thereof at least one therapeutically effective amount selected from the group consisting of the strain of any one of claims 1 to 6, the culture of the strain, the lysate of the strain, and the extract of the strain. A method of treating an autoimmune disease or inflammatory disease comprising a.

20. For use in preventing or treating intestinal diseases comprising at least one selected from the group consisting of the strain of any one of claims 1 to 6, the culture of the strain, the lysate of the strain, and the extract of the strain. Composition.

21. For use in the prevention or treatment of allergic diseases comprising at least one selected from the group consisting of the strain of any one of claims 1 to 6, the culture of the strain, the lysate of the strain, and the extract of the strain. Composition.

22. Use of preventing or treating autoimmune diseases or inflammatory diseases comprising at least one selected from the group consisting of the strain of any one of claims 1 to 6, the culture of the strain, the lysate of the strain, and the extract of the strain. Composition for use as.

23. To prepare a drug for preventing or treating intestinal diseases comprising at least one selected from the group consisting of the strain of any one of claims 1 to 6, the culture of the strain, the lysate of the strain, and the extract of the strain. Use of the composition for.

24. To prepare a drug for preventing or treating allergic diseases comprising at least one selected from the group consisting of the strain of any one of claims 1 to 6, the culture of the strain, the lysate of the strain, and the extract of the strain. Use of the composition for.

25. For the prevention or treatment of an autoimmune disease or inflammatory disease comprising at least one selected from the group consisting of the strain of any one of claims 1 to 6, the culture of the strain, the lysate of the strain, and the extract of the strain. Use of the composition for preparing a medicament.